Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 5/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 10/20 | 0.37 |
| ▸ | FPR2 | P25090 | 3/20 | 0.35 |
| ▸ | FPR1 | P21462 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 6/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4680777 | 0.92 | ROCK2 (0.40) | ROCK2BTKF10FPR2FPR1 | |
| SCHEMBL4683540 | 0.76 | F10 (0.41) | F10FPR2F2PRSS1 | |
| SCHEMBL6325742 | 0.73 | ROCK2 (0.45) | ROCK2F10FPR2FPR1F2 | |
| SCHEMBL6984323 | 0.67 | F10 (0.48) | ROCK2F10FPR2FPR1 | |
| SCHEMBL6986765 | 0.67 | F10 (0.48) | ROCK2F10FPR2FPR1 | |
| SCHEMBL6988835 | 0.66 | F10 (0.47) | F10FPR2 | |
| SCHEMBL7090495 | 0.65 | F10 (0.46) | ROCK2F10FPR2FPR1 | |
| SCHEMBL6984261 | 0.64 | F10 (0.49) | ROCK2F10FPR2FPR1 | |
| SCHEMBL6985267 | 0.62 | FPR2 (0.55) | F10FPR2FPR1 | |
| SCHEMBL4683261 | 0.62 | F10 (0.42) | F10FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1337251-A1 | MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002102380-A1 | MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-12-27 | — | — | WO | disclosed |